Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea

Journal of Human Hypertension

Volumn 29, Issue 12, 2015, Pages 713-718

  Cai, W ^a   Sun, J F ^a   Liu, Y ^a   Xu, J X ^a   Xiao, J R ^a   Duan, X M ^a   Liu, J Y ^a   Zhang, W ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ENDOGENOUS SECRETORY ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOLUBLE ADVANCED GLYCATION END PRODUCT RECEPTOR; UNCLASSIFIED DRUG; ESRAGE PROTEIN, HUMAN; SRAGE PROTEIN, HUMAN;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PROTEIN BLOOD LEVEL; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BLOOD; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; BLOOD PRESSURE; HUMANS; MALE; MIDDLE AGED; SLEEP APNEA, OBSTRUCTIVE;

EID: 84947032265     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2015.46     Document Type: Article

References (34)

1. Durán J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med 2001; 163: 685-689.
2. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large communitybased study. Sleep Heart Health Study. JAMA 2000; 283: 1829-1836.
3. Lenfant C, Chobanian AV, Jones DW, Roccella EJJoint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
4. Baguet JP, Barone-Rochette G, Pápin JL. Hypertension and obstructive sleep apnoea syndrome: current perspectives. J Hum Hypertens 2009; 23: 431-443.
5. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Investig 1995; 96: 1897-1904.
6. Elmasry A, Lindberg E, Hedner J, Janson C, Boman G. Obstructive sleep apnoea and urine catecholamines in hypertensive males: a population-based study. Eur Respir J 2002; 19: 511-517.
7. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266: 11654-11660.
8. Xu Y, Toure F, Qu W, Lin L, Song F, Shen X, et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem 2010; 285: 23233-23240.
9. Tan KC, Chow WS, Lam JC, Lam B, Bucala R, Betteridge J, et al. Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea. Sleep 2006; 29 (3): 329-333.
10. Lam JC, Tan KC, Lai AY, Lam DC, Ip MS. Increased serum levels of advanced glycation end-products is associated with severity of sleep disordered breathing but not insulin sensitivity in non-diabetic men with obstructive sleep apnoea. Sleep Med 2012; 13: 15-20.
11. Celec P, Hodosy J, Behuliak M, Pálffy R, Gardlík R, Hal?ák L, et al. Oxidative and carbonyl stress in patients with obstructive sleep apnea treated with continuous positive airway pressure. Sleep Breath 2012; 16: 393-398.
12. Kotani K, Kimura S, Komada I, Sakane N, Gugliucci A. Continuous positive air pressure treatment reduces serum advanced glycation end products in patients with obstructive sleep apnoea syndrome: a pilot study. Prim Care Respir J 2011; 20 (3): 336-337.
13. Xu JX, Cai W, Sun JF, Liao WJ, Liu Y, Xiao JR, et al. Serum advanced glycation end products are associated with insulin resistance in male nondiabetic patients with obstructive sleep apnea. Sleep Breath (e-pub ahead of print 2 January 2015; doi: 10.1007/s11325-014-1100-z).
14. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-822.
15. Elmasry A, Lindberg E, Hedner J, Janson C, Boman G. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009; 20: 742-752.
16. Yan SF, Ramasamy R, Schmidt AM. The RAGE Axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010; 106: 842-853.
17. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, et al. Identification, classification, an expression of RAGE gene splice variants. FASEB J 2008; 22: 1572-1580.
18. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-2835.
19. YanS F, D'Agati V, Schmidt AM, Ramasamy R. Receptor for Advanced Glycation End products (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 2007; 7: 699-710.
20. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K, et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 2006; 55: 2245-2255.
21. Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005; 23: 1725-1729.
22. Momma H, Niu K, Kobayashi Y, Huang C, Chujo M, Otomo A, et al. Lower serum endogenous secretory receptor for advanced glycation end product level as a risk factor of metabolic syndrome among Japanese adult men: a 2-year longitudinal study. J Clin Endocrinol Metab 2014; 99: 587-593.
23. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98: 772-776.
24. Narkiewicz K, Somers VK. Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol Scand 2003; 177: 385-390.
25. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097-1109.
26. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009; 204: 288-292.
27. Katakami N, Matsuhisa M, Kaneto H, Yamasaki Y. Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 2007; 190: 22-23.
28. Koyama H, Yamamoto H, Nishizawa Y. Endogenous secretory RAGE as a novel biomarker for metabolic syndrome and cardiovascular diseases. Biomark Insights 2007; 2: 331-339.
29. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 2587-2593.
30. Hudson BI, Dong C, Gardener H, Elkind MS, Wright CB, Goldberg R, et al. Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan Study. Metabolism 2014; 63: 1125-1130.
31. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation end products(RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22: 3716-3727.
32. Ohe K, Watanabe T, Harada SI, Munesue S, Yamamoto Y, Yonekura H, et al. Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein H. J. Biochem 2010; 147: 651-659.
33. Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006; 55: 1227-1231.
34. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diabetes Vasc Dis Res 2008; 5: 190-197.